Tag:

prostate cancer

Latest Headlines

Latest Headlines

Odoreader showing promise as urological 'smell' test for prostate cancer

A urological "smell" test for prostate cancer is snaking its way through the R&D process. The University of the West of England's Urological Institute team at Southmead Hospital and the Bristol Royal Infirmary said a pilot of the diagnostic showed promise on 155 men, 58 of whom had prostate cancer and 24 of whom had bladder cancer.

Qiagen backs liquid biopsy startup Exosome in $60M Series B

Diagnostics giant Qiagen has joined the syndicate of Exosome Diagnostics--helping to distinguish this liquid biopsy startup from its growing crowd of peers. The pair are already partnered under a 2014 lung cancer diagnostic development deal. The Cambridge, MA-based startup has raised a $60 million Series B round to launch its liquid biopsy test via its CLIA-certified lab as well as to seek out companion diagnostics deals with biopharmas.

Roche bags a preclinical next-gen prostate cancer program in $142M deal

Roche has stepped in to in-license the preclinical work of two Canadian investigators who have been focused on inhibiting all forms of the androgen receptor in an effort to find new drugs that can step in after prostate cancer patients become resistant to the first wave of drugs now on the market.

Bone microenvironment offers new approach on prostate cancer

Studying the bone microenvironment may offer new insights into better drugs for fighting prostate cancer metastasis.

Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat

With a new first-line approval last year in metastatic prostate cancer, Medivation and Astellas' Xtandi was set up for a head-to-head fight against Johnson & Johnson's Zytiga. Some analysts figured Xtandi would skate to first place. But it hasn't turned out that way--and now, Medivation is putting some more money behind its drug to change course.

FDA green-lights innovative prostate ablation ultrasound device

SonaCare Medical snagged an FDA OK for its prostate ablation ultrasound device, broadening its international footprint months after ramping up sales for the device in Europe.

Myriad inks coverage deal for prostate cancer test

Myriad Genetics has inked a three-year contract with Tufts Health Plan to provide its Prolaris biopsy test for members diagnosed with localized prostate cancer.

Myriad inks coverage deal for prostate cancer test

Myriad Genetics has inked a three-year contract with Tufts Health Plan to provide its Prolaris biopsy test for members diagnosed with localized prostate cancer.

Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive

Private equity group Essex Woodlands has snapped up a 16% stake in surgical peripheral nerve solutions company AxoGen. The company raised $17.5 million to back its existing regenerative medicine products, as well as to develop new candidates for nerves severed during prostate cancer surgery and lower extremity nerve injuries. The financing is expected to put the company in the black for the first time.

Myriad snags Medicare coverage for prostate cancer test

Myriad Genetics nabbed Medicare coverage for its prostate cancer screening test, a win for the company as it struggles with waning revenues and increased competition from rivals in the genetic testing market.